FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145816380> ?p ?o ?g. }

• W2145816380 endingPage "2964" @default.
• W2145816380 startingPage "2960" @default.
• W2145816380 abstract "Tumour lysis syndrome (TLS) is a complication associated with the treatment of tumour types with high proliferative rate, large tumour burden or high sensitivity to cytotoxic therapy. The implementation of risk stratification strategies [1], appropriate prophylactic measures, vigilant monitoring of laboratory parameters and active interventions to reduce risk factors has dramatically decreased the incidence of clinically significant morbidity that results in end organ damage and mortality. Despite these advances, 5–6% of atrisk paediatric and adult patients undergoing chemotherapy develop acute kidney injury (AKI), and 40–50% of these patients will require dialysis therapies with associated allcause mortality in excess of 50% [2–4]. Similar outcomes are reported with spontaneous TLS [5]. The lack of standardized definitions and outcome measures has hampered appreciation of the extent of adverse renal outcomes in TLS. Recent adoption of a uniform definition of AKI (increase in serum creatinine of 0.3 mg/dL from baseline or a 50% increase in serum creatinine from baseline values within 48 h) [6] and the recognition that the development of in-hospital AKI have significant implications for long-term mortality [7] underscores the need to understand the mechanisms involved in AKI associated with TLS. Furthermore, the effect of chronic kidney disease (CKD) on renal outcomes in TLS requires a study, as clinical tumour lysis occurs more frequently in patients with pretreatment renal impairment [8]. One study examining risk factors for in-hospital AKI of diverse aetiologies reported that CKD increases the risk of AKI 40-fold with a 20-fold increased risk for dialysis [9]. Here, we will briefly review the current understanding of the pathogenesis of TLS-induced AKI. In particular, a recent literature suggests that AKI and nephropathy are not simply due to intrarenal crystal deposition of urate and phosphate. Mechanism of AKI associated with intrarenal deposition of uric acid crystals TLS is a group of metabolic complications that occur after the treatment of large volume, rapidly proliferating haematological cancers including not only acute leukaemia and aggressive lymphomas but also some solid tumours. Metabolic alterations that result include hyperkalaemia, hyperphosphataemia, hyperuricaemia and hyperuricosuria, hypocalcaemia and consequent AKI. Specifically, AKI associated with TLS has been considered to be exclusively a crystal-dependent process caused by the massive and abrupt release of intracellular metabolites from chemosensitive, rapidly proliferating tumour cells that undergo rapid lysis and release nucleic acid breakdown products, phosphorus and potassium. Both urate and calcium phosphate crystals may cause crystal-dependent injury of the kidney which overwhelms the normal homeostatic mechanism(s) autoregulating normal renal physiology [10]. One of the most important mediators of AKI resulting from TLS is uric acid. When dying cells release DNA and RNA, they are degraded in the liver and other sites with the rapid production of uric acid. Serum uric acid rises acutely, resulting in marked uricosuria. Such cell death and degradation also results in acid generation, often with volume depletion, resulting in acidic urine that decreases the solubility of uric acid. When levels of urinary uric acid exceed its solubility, both micro- and macrocrystal formations occur in the distal tubules and collecting ducts with obstruction of the tubular lumen. The prevention of AKI resulting from TLS includes initiating prophylactic measures prior to and during chemotherapy, including hydration, alkalinization of the urine, use of the xanthine oxidase inhibitor allopurinol, as well as the urate oxidase inhibitor, rasburicase or its derivatives." @default.
• W2145816380 created "2016-06-24" @default.
• W2145816380 creator A5004471228 @default.
• W2145816380 creator A5004801919 @default.
• W2145816380 creator A5008312390 @default.
• W2145816380 creator A5031789061 @default.
• W2145816380 creator A5031853527 @default.
• W2145816380 creator A5043202842 @default.
• W2145816380 creator A5050795724 @default.
• W2145816380 creator A5081242770 @default.
• W2145816380 creator A5085254307 @default.
• W2145816380 date "2009-07-06" @default.
• W2145816380 modified "2023-10-16" @default.
• W2145816380 title "A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome" @default.
• W2145816380 cites W1512668381 @default.
• W2145816380 cites W1605032945 @default.
• W2145816380 cites W1940749453 @default.
• W2145816380 cites W1963591576 @default.
• W2145816380 cites W1967300023 @default.
• W2145816380 cites W1969406223 @default.
• W2145816380 cites W1985749449 @default.
• W2145816380 cites W1987368075 @default.
• W2145816380 cites W1992405112 @default.
• W2145816380 cites W2002189955 @default.
• W2145816380 cites W2016207805 @default.
• W2145816380 cites W2025372788 @default.
• W2145816380 cites W2027422803 @default.
• W2145816380 cites W2029417334 @default.
• W2145816380 cites W2031005241 @default.
• W2145816380 cites W2033219827 @default.
• W2145816380 cites W2034707276 @default.
• W2145816380 cites W2037926286 @default.
• W2145816380 cites W2043172105 @default.
• W2145816380 cites W2046572840 @default.
• W2145816380 cites W2046679370 @default.
• W2145816380 cites W2050906978 @default.
• W2145816380 cites W2051640837 @default.
• W2145816380 cites W2056286076 @default.
• W2145816380 cites W2057163533 @default.
• W2145816380 cites W2065486513 @default.
• W2145816380 cites W2066833271 @default.
• W2145816380 cites W2067363944 @default.
• W2145816380 cites W2067503609 @default.
• W2145816380 cites W2077357748 @default.
• W2145816380 cites W2081789009 @default.
• W2145816380 cites W2090127336 @default.
• W2145816380 cites W2090952723 @default.
• W2145816380 cites W2092157690 @default.
• W2145816380 cites W2104681259 @default.
• W2145816380 cites W2106403351 @default.
• W2145816380 cites W2107997910 @default.
• W2145816380 cites W2108997307 @default.
• W2145816380 cites W2112250644 @default.
• W2145816380 cites W2116061272 @default.
• W2145816380 cites W2123162884 @default.
• W2145816380 cites W2125942122 @default.
• W2145816380 cites W2132895884 @default.
• W2145816380 cites W2136298697 @default.
• W2145816380 cites W2141234027 @default.
• W2145816380 cites W2142972994 @default.
• W2145816380 cites W2146179253 @default.
• W2145816380 cites W2146325614 @default.
• W2145816380 cites W2158256731 @default.
• W2145816380 cites W2159922642 @default.
• W2145816380 cites W2161379839 @default.
• W2145816380 cites W2162513902 @default.
• W2145816380 cites W2164300869 @default.
• W2145816380 cites W2164965999 @default.
• W2145816380 cites W2166980815 @default.
• W2145816380 cites W2168185962 @default.
• W2145816380 cites W2171576765 @default.
• W2145816380 cites W2171616231 @default.
• W2145816380 cites W21933792 @default.
• W2145816380 doi "https://doi.org/10.1093/ndt/gfp330" @default.
• W2145816380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19581334" @default.
• W2145816380 hasPublicationYear "2009" @default.
• W2145816380 type Work @default.
• W2145816380 sameAs 2145816380 @default.
• W2145816380 citedByCount "114" @default.
• W2145816380 countsByYear W21458163802012 @default.
• W2145816380 countsByYear W21458163802013 @default.
• W2145816380 countsByYear W21458163802014 @default.
• W2145816380 countsByYear W21458163802015 @default.
• W2145816380 countsByYear W21458163802016 @default.
• W2145816380 countsByYear W21458163802017 @default.
• W2145816380 countsByYear W21458163802018 @default.
• W2145816380 countsByYear W21458163802019 @default.
• W2145816380 countsByYear W21458163802020 @default.
• W2145816380 countsByYear W21458163802021 @default.
• W2145816380 countsByYear W21458163802022 @default.
• W2145816380 countsByYear W21458163802023 @default.
• W2145816380 crossrefType "journal-article" @default.
• W2145816380 hasAuthorship W2145816380A5004471228 @default.
• W2145816380 hasAuthorship W2145816380A5004801919 @default.
• W2145816380 hasAuthorship W2145816380A5008312390 @default.
• W2145816380 hasAuthorship W2145816380A5031789061 @default.
• W2145816380 hasAuthorship W2145816380A5031853527 @default.
• W2145816380 hasAuthorship W2145816380A5043202842 @default.

• next